{"id":46317,"date":"2022-07-19T15:01:43","date_gmt":"2022-07-19T13:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-study-of-aerin-medicals-rhinaer-shows-positive-clinical-and-quality-of-life-results-following-treatment-for-chronic-rhinitis\/"},"modified":"2022-07-19T15:01:43","modified_gmt":"2022-07-19T13:01:43","slug":"new-study-of-aerin-medicals-rhinaer-shows-positive-clinical-and-quality-of-life-results-following-treatment-for-chronic-rhinitis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-study-of-aerin-medicals-rhinaer-shows-positive-clinical-and-quality-of-life-results-following-treatment-for-chronic-rhinitis\/","title":{"rendered":"New Study of Aerin Medical\u2019s RhinAer\u00ae Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis"},"content":{"rendered":"
\n

\nLargest study of RhinAer to date shows 87% of patients reported quality-of-life improvements<\/i>\n<\/p>\n

SUNNYVALE, Calif.–(BUSINESS WIRE)–#ENT<\/a>—Aerin Medical Inc<\/a>., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy<\/a><\/i>. RELIEF demonstrated that treatment yielded a clinically significant improvement in all chronic rhinitis symptoms and quality-of-life (QoL) at three- and six-months following RhinAer\u00ae<\/sup> treatment. Additionally, the study demonstrated that the procedure was well-tolerated by patients.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cChronic rhinitis can be a frustrating condition for patients as the symptoms are often poorly controlled with current treatments like nasal sprays and other medications,\u201d said Elina Toskala, M.D., Ph.D., MBA, Professor, Rhinology and Skull Base Surgery, Department of Otolaryngology \u2013 Head and Neck Surgery, Thomas Jefferson University in Philadelphia, and investigator of the RELIEF clinical trial. \u201cThis new international, multi-center study demonstrates that treatment with a temperature-controlled radiofrequency device shows a sustained improvement in chronic rhinitis symptoms, cough and post-nasal drip as well as quality-of-life measures through 6 months. The procedure was shown to be well-tolerated with no post-procedural headaches reported.”\n<\/p>\n

\nRELIEF, a prospective, single-arm, multi-center study, enrolled 129 adults with chronic rhinitis at 16 centers in the United States and Germany and evaluated clinical outcomes and QoL in those who were treated with RhinAer. The RELIEF study met its primary and secondary endpoints, demonstrating that treatment of the posterior nasal nerve (PNN) area with RhinAer was safe and significantly reduced major chronic rhinitis symptoms at three- and six-months following treatment. Findings included:\n<\/p>\n